The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Amyotrophic Lateral Sclerosis
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
-
University of California San Diego, La Jolla, California, United States, 92037
Stanford University Medical Center, Palo Alto, California, United States, 94304
Johns Hopkins University, Baltimore, Maryland, United States, 21205
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
Columbia University Medical Center, New York, New York, United States, 10032
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States, 43210
University of Utah, Salt Lake City, Utah, United States, 84132
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
10 Years to
ALL
No
Ionis Pharmaceuticals, Inc.,
2028-03